Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Description of Role
The Director, External Quality Control & Stability will provide leadership and oversight for analytical testing, stability programs, specification management, and quality control activities supporting clinical and commercial development.
Key Responsibilities
Analytical Oversight and Tactical Support
- Develop and Lead analytical quality control strategy across multiple programs.
- Review analytical methods, specifications, and validation activities for adequacy and collaborate on updates, as required.
- Support analytical method transfer, as required
- Collaborate on supplier qualification and/or remediation activities.
Stability Program Leadership
- Oversee the stability program design and execution across multiple programs.
- Monitor and report on stability trends and product quality attributes as required.
- Ensure ongoing regulatory compliance of stability activities.
Supplier Oversight
- Manage supplier ongoing relationships.
- Perform routine reviews of testing results and overall quality of documentation.
- Drive issue resolution to facilitate regulatory compliance.
Regulatory Support
- Provide tactical support for regulatory submissions
- Support health authority inspections and audits, as required.
- Review analytical and stability sections within CMC filings.
Qualifications
- BS/MS/PhD in Chemistry, Analytical Chemistry, Pharmaceutical Sciences, or related field.
- 10+ years quality control and analytical development experience.
- Experience developing strategic vision as well as providing tactical support for quality control programs
Compensation
The annual base salary range for this position is $150,000.00 to $210,000.00. Individual compensation within this range will be determined based on a variety of factors, including location, qualifications, skills, relevant experience, and job knowledge.
In addition to base pay, this role is eligible for a discretionary annual bonus. The Company also offers a comprehensive benefits package, which includes a 401(k) plan, company-sponsored medical, dental, vision, and life insurance, generous paid time off, and a health and wellness program.
Work Location
The Director, External Quality Control & Stability role is a remote role based in the US.
POSITION: Temporary, non-exempt
EEOC Statement: Centessa Pharmaceuticals, a wholly owned subdisary of Eli Lilly and Company believes in a diverse environment and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion, or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. We will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Please note: We will not assign referral rights for any unsolicited resumes from recruitment agencies.
Centessa Pharmaceuticals Boston, Massachusetts, USA Office
1 Federal Street. 38th Floor, Boston, MA, United States, 02110
Similar Jobs
What you need to know about the Boston Tech Scene
Key Facts About Boston Tech
- Number of Tech Workers: 269,000; 9.4% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Thermo Fisher Scientific, Toast, Klaviyo, HubSpot, DraftKings
- Key Industries: Artificial intelligence, biotechnology, robotics, software, aerospace
- Funding Landscape: $15.7 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Summit Partners, Volition Capital, Bain Capital Ventures, MassVentures, Highland Capital Partners
- Research Centers and Universities: MIT, Harvard University, Boston College, Tufts University, Boston University, Northeastern University, Smithsonian Astrophysical Observatory, National Bureau of Economic Research, Broad Institute, Lowell Center for Space Science & Technology, National Emerging Infectious Diseases Laboratories
